Reshma Kewalramani

CEO, President | Vertex Pharmaceuticals

626th

in Fortune Global 1000

915th

in Forbes Global 2000

Reshma has dedicated her career to improving the lives of patients, spending more than 15 years in the development of new medicines prior to becoming the CEO and president at Vertex. Under her leadership, Vertex has made significant progress in the development of medicines for cystic fibrosis patients around the world and has advanced several programs outside of cystic fibrosis into the clinic. Before joining Vertex, Reshma was at Amgen for twelve years where her roles included VP of Global Clinical Development, Nephrology and Metabolic Therapeutic Area. Reshma received her medical degree from Boston University through the seven-year program and completed her residency at the Massachusetts General Hospital and her fellowship in nephrology. She also completed the General Management Program at Harvard Business School.

Reshma is a member of the board of directors for the Biomedical Science Careers Program committed to supporting underrepresented students in the fields of STEM. She is also a member of the board for RIZE Massachusetts. In response to the COVID-19 pandemic, the Vertex Foundation has committed $5 million to organizations who are providing relief to affected communities.